5-Amino-1MQ Guide: What the NNMT Evidence Actually Shows

5-Amino-1MQ arrives with an unusual evidence profile: a clean, well-published molecular mechanism sitting on top of an empty human trial registry. That gap is where most of the confusion lives, and where marketing tends to fill in the blanks. This guide separates what rodents and cell cultures have shown from what people are actually doing, and states the evidence stage for every claim it makes.

Key takeaways#

• 5-Amino-1MQ blocks nicotinamide N-methyltransferase (NNMT). In cultured adipocytes, the compound raised NAD+ roughly 1.2 to 1.6-fold and significantly raised SAM, as reported in the patent record behind the published pharmacology.
• Zero human trials exist. Independent registry checks in August 2026 of ClinicalTrials.gov for 5-Amino-1MQ, 5-amino-1-methylquinolinium and 5A1MQ each returned no registered study at any phase.
• In a 30-day mouse study at 10 and 32 mg/kg/day, fat mass and body weight gains fell in a dose-dependent way versus saline control, with eight animals per arm.
• The oral range that circulates in vendor and community protocols is roughly 50 mg to 150 mg daily. That range comes from anecdotal practice, not from any published trial.
• 5-Amino-1MQ has no FDA approval and does not meet the standard eligibility routes for 503A compounding, so supply runs through research-chemical channels where quality varies.

5-Amino-1MQ Blocks the NNMT Enzyme to Shift Fat Cell Metabolism#

5-Amino-1MQ is a small molecule that blocks nicotinamide N-methyltransferase, an enzyme overexpressed in fat tissue. In rodent and cell studies, that block raises intracellular NAD+ and SAM and lowers fat storage signalling. All published evidence remains preclinical, with no human trials measuring these effects in people.

The chemistry matters for how you read everything downstream. Despite being sold beside peptides, 5-Amino-1MQ is not one: it is a methylquinolinium salt with no amino acid chain. As an NNMT inhibitor it competes at the enzyme that normally attaches a methyl group to nicotinamide, producing 1-methylnicotinamide (1-MNA) and consuming S-adenosylmethionine (SAM) in the process.

Neelakantan and colleagues built the methylquinolinium series specifically for membrane permeability and selectivity, then showed in cultured fat cells that the inhibitors lowered 1-MNA, raised NAD+ and SAM, and suppressed lipogenesis. A 2024 review of NNMT as a metabolic target notes that this NNMT inhibitor class shows no inhibitory effect on other SAM-dependent methyltransferases or NAD+ salvage enzymes, which is what makes the target engagement argument readable rather than hand-waved. Every measurement in that chain comes from cells and mice.

Preclinical Rodent Studies Show Fat Mass Reduction Without Calorie Restriction#

Rodent studies have shown fat mass falling without any change in food intake, which is the single most interesting feature of the preclinical record. In diet-induced obese mice on a high-fat diet, systemic administration of a potent NNMT inhibitor reduced body weight and white adipose mass, shrank adipocytes, and lowered plasma total cholesterol, with no impact on total food intake and no observable adverse effects in that model.

The largest metabolic study to date ran 30 days. Babula and colleagues randomised diet-induced obese mice to saline, 10 mg/kg/day or 32 mg/kg/day of 5A1MQ by once-daily subcutaneous injection, eight animals per group, and tracked body composition by EchoMRI. Treatment dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia. A 2021 Scientific Reports study paired the compound with a switch to a lean diet and reported that the combination normalised adiposity toward age-matched lean animals faster than the diet switch alone.

Preclinical evidence · DIO mice, 30 days

The high dose held fat gain to roughly a quarter of control

Each row pairs one treated arm with its saline control. The gap is the treatment effect; the low dose moved body weight barely at all.

Dose separation is real

• The 10 mg/kg arm tracked control on body weight.
• Only the 32 mg/kg arm separated clearly.

Read the units

• These are grams gained by mice, not kilograms lost by people.

No Published Human Clinical Trials Currently Exist for 5-Amino-1MQ#

No human clinical trial of 5-Amino-1MQ has been registered or published, at any phase, anywhere. Registry checks run in August 2026 against ClinicalTrials.gov under the common name, the full chemical name 5-amino-1-methylquinolinium and the abbreviation 5A1MQ each returned a total count of zero studies. A broader search on the NNMT term surfaced only unrelated records.

That absence has specific consequences. There is no human pharmacokinetic profile, no dose-ranging work, no safety database and no efficacy endpoint measured in people. Every number quoted anywhere in this guide describes a mouse, a rat or a cell line.

The animal record is also narrow in ways worth naming. The metabolic studies used male diet-induced obese mice almost exclusively, the muscle work used aged mice of one sex per study, and the longest exposure located in the published literature runs about eight weeks. No non-rodent species work, and no reproductive, developmental or carcinogenicity studies, appear in the public record. Preliminary evidence of this kind establishes a hypothesis worth testing. It does not establish a human effect size.

NNMT Inhibition Links 5-Amino-1MQ to NAD+ and SAM Metabolic Pathways#

NNMT inhibition changes two currencies at once, and that dual effect is the mechanistic core of the compound. Each methylation reaction NNMT performs consumes one SAM molecule and removes one nicotinamide from the NAD+ salvage pathway. Slow the enzyme down and both pools are spared inside the cell.

The patent record behind the published pharmacology quantifies it: in differentiated adipocytes, 5-amino-1MQ at 1 to 60 micromolar produced a concentration-dependent NAD+ rise of roughly 1.2 to 1.6-fold versus untreated controls, with a statistically significant increase at 10 micromolar, and a significant main effect on intracellular SAM at the higher concentrations. Reviews note that inhibiting or knocking down NNMT has been shown to raise NAD+ consistently in mouse adipocytes and hepatocytes, while NNMT overexpression in mouse liver lowers it.

Mechanism · rodent and cell-culture data

One blocked enzyme spares two metabolic currencies at once

Blocking NNMT reduces 1-MNA output, which leaves more nicotinamide for NAD+ salvage and more SAM for methylation reactions.

People Consider 5-Amino-1MQ for Weight Management, Metabolic Support, and Healthy Aging Goals#

Three goals drive most interest in this compound, and each traces to a different preclinical paper. Weight management interest comes from the diet-induced obesity work. Metabolic support interest comes from the glucose tolerance and insulin sensitivity findings in the same rodent models. Healthy aging interest comes from a separate line of muscle research.

That third line is often overlooked. Neelakantan and colleagues reported in 2019 that NNMT protein is elevated in aged skeletal muscle, and that treating 24-month-old mice with an NNMT inhibitor after muscle injury roughly doubled myofiber cross-sectional area and increased peak torque of the treated muscle by about 70% versus controls. Muscle stem cell proliferation and fusion both rose.

Read as a hypothesis, that is a coherent healthy aging story: an enzyme that climbs with age, draining a cofactor that also falls with age. Read as a human claim, it is a mouse injury model. Preclinical data points toward a mechanism worth studying in people, and nothing published yet closes that distance.

Typical Research Protocols Use Oral Dosing in the 50mg to 150mg Range#

The 5-Amino-1MQ dosage figures in circulation are 50 mg to 150 mg taken orally once daily, usually in capsule form. That range originates in vendor literature and user-reported protocols. It does not originate in a trial, because no human trial exists to have produced it.

The published animal dosing looks nothing like it. The 30-day mouse study used 10 and 32 mg/kg/day by subcutaneous injection. The earlier 11-day proof-of-concept used 20 mg/kg three times daily, also subcutaneously. Allometric scaling between species is unreliable at the best of times, and it is not the basis of the oral figures people quote.

Oral absorption is the specific weak point. The 2024 study characterised plasma pharmacokinetics after intravenous, oral and subcutaneous dosing, and the two published oral bioavailability figures for this molecule, one in rat and one in mouse, differ from each other by roughly elevenfold. Any 5-Amino-1MQ dosage conversation that skips this disagreement is quoting a number without its error bar.

Effects Reported in Preclinical and Anecdotal Sources Emerge Over Weeks, Not Days#

The honest answer to how long 5-Amino-1MQ takes to work is that nobody has measured it in a person. What exists is a rodent timeline and a body of self-reported experience, and the two roughly agree on a scale of weeks.

In the 11-day mouse study, body weight differences between treated and control animals reached statistical significance around day six and widened through days nine and ten. In the 30-day study, body composition was tracked at days 8, 15, 23 and 29, with separation building across those points rather than appearing at the first measurement. The 2021 diet-switch work ran about seven weeks before termination.

Anecdotal reports follow a similar shape: energy and endurance changes described first, body composition changes described later, typically after four to eight weeks. Those reports carry no placebo control and no verification of what was actually in the capsule. Anyone asking how long 5-Amino-1MQ takes to work should treat both sources as directional at best, and should expect nothing on a scale of days.

Reported Side Effects Remain Limited to Preclinical Observation and Anecdotal Reports#

All 5-Amino-1MQ side effects described anywhere come from two sources: rodent observation and user self-report. Neither is a safety database.

On the preclinical side, the 2018 obesity study reported no observable adverse effects in the treated animals, and no change in food intake. The 2024 study screened the compound against a broad receptor and enzyme panel and characterised tissue distribution. Those are reassuring signals within their species and their exposure window, which topped out at roughly four to eight weeks.

On the anecdotal side, the 5-Amino-1MQ side effects most commonly described are mild and non-specific: digestive upset, headache, and sleep disturbance when taken late in the day. Self-reports of this kind cannot separate compound effects from expectation, from co-administered supplements, or from contaminants in unverified material.

What is missing matters more than what is reported. No reproductive, developmental, carcinogenicity or immunogenicity studies exist. NNMT is also implicated in tumour biology in several tissues, which is a reason to want long-horizon human safety work rather than a reason to assume harm.

5-Amino-1MQ Is Not FDA-Approved and Falls Outside Standard Compounding Categories#

The 5-Amino-1MQ FDA status is straightforward: no approval, no approved label, and no publicly disclosed Investigational New Drug application. It is sold as a research chemical, and in the United States that classification carries no premarket review of identity, purity or potency.

The compounding question is a separate one, and it is where marketing language most often blurs. Under section 503A, a bulk substance can generally be used by a compounding pharmacy only if it is the subject of a USP or NF monograph, is a component of an FDA-approved product, or appears on the FDA's 503A bulks list. 5-Amino-1MQ meets none of those routes. The FDA maintains a public page of bulk substances nominated for 503A use, and a January 2025 guidance ended the Category 1, 2 and 3 scheme for substances nominated after that date.

A category listing is a stage in a nomination process, not an approval. Klarovel states regulatory position plainly rather than implying one; our disclosures page explains how we frame research-stage compounds.

5-Amino-1MQ Differs From NAD+ Precursors Like NR and NMN in Mechanism, Not Goal#

Comparing 5-Amino-1MQ vs NR and NMN is a comparison of two routes to one destination. The precursors add raw material to the NAD+ pool from outside. The NNMT inhibitor reduces the rate at which nicotinamide is methylated away inside tissues where NNMT is highly expressed, particularly white adipose tissue.

The evidence stages differ sharply, and that difference is the practical part of the comparison. NR and NMN have been studied in humans repeatedly, with trials reporting measurable increases in blood NAD+ at gram-level daily doses. NR retains US dietary supplement status with a self-affirmed GRAS position; NMN was excluded from the supplement definition in November 2022 under the drug preclusion provision, a position the agency later amended after citizen petitions. 5-Amino-1MQ has no human data at all.

One mechanistic distinction is real and not shared: sparing SAM. NAD+ precursors do not address methyl-donor depletion. For the deeper breakdown of precursor supplementation, see our guide to NAD+ and its precursors.

Mechanism contrast · different evidence stages

Two routes to the same NAD+ pool, at two very different evidence stages

The left route reduces local loss in rodent fat tissue. The right route adds substrate and has been measured in human blood.

Certain Populations Should Avoid 5-Amino-1MQ Given Limited Safety Data#

The question of who should not take 5-Amino-1MQ has a wider answer than usual, because the safety data that would narrow it does not exist. Pregnancy and breastfeeding sit at the top of that list: no reproductive or developmental studies have been published, in any species.

Anyone with an active or historical cancer diagnosis has a second, mechanism-specific reason for caution. NNMT is overexpressed in several tumour types and has been associated with migration, invasion and stromal remodelling in published cell work. Pharmacological NNMT inhibition in that setting has not been characterised in people.

Beyond those two groups, who should not take 5-Amino-1MQ reasonably extends to anyone under 18, anyone with significant liver or kidney impairment, and anyone on a medicine regimen they have not reviewed with a prescriber. The rodent studies concentrated on liver endpoints for a reason: that organ carries much of the metabolic load. Without human pharmacokinetics, interaction risk cannot be estimated, only guessed at.

Sourcing Quality Varies Across Research Suppliers and Compounding Channels#

Supplier variation is the most underrated risk in this entire topic. Because 5-Amino-1MQ is neither an approved product nor an eligible compounding substance, everything sold under that name reaches buyers through research-chemical supply chains with no mandated identity or purity testing.

What separates serious suppliers is documentation. A batch-specific certificate of analysis, with HPLC or LC-MS identity and purity data tied to the lot number on the container, is the minimum. Third-party verification, rather than an in-house PDF, is the meaningful step above that. Heavy metal and residual solvent screens matter for an orally taken material.

Klarovel does not sell or stock peptides or research compounds, and earns nothing on anything bought elsewhere. Sourcing is the reader's own arrangement. Research-grade 5-Amino-1MQ is available from specialised suppliers, and the quality spread across those suppliers is wide enough to change what a person is actually taking. A certificate of analysis is the only document that speaks to what was in the vial when it shipped, and our guide to storing and handling peptides covers why that document stops describing the material once storage conditions slip.

Claims That NAD+ and 5-Amino-1MQ Amplify Each Other Rest on Shared Pathways, Not Combined Trials#

Stacking claims about NAD+ precursors and 5-Amino-1MQ are mechanism-only claims, and they should be labelled that way every time. The reasoning is legitimate: one approach adds nicotinamide to the system while the other reduces the rate at which it is methylated away, so the two act at different points on the same pathway.

Published reviews go as far as noting that combining small-molecule NNMT inhibitors with NAD+ precursor supplements may support better outcomes in metabolic models and could allow lower precursor doses. That is a stated hypothesis in a review, drawn from separate rodent literatures.

No combined trial exists. There is no human study of 5-Amino-1MQ alone, which makes a controlled human study of 5-Amino-1MQ plus NR or NMN structurally impossible to have run. Nobody has measured whether the two produce a supra-additive response in people, an additive one, or no detectable difference from the precursor alone. Anyone presenting the pairing as validated is describing a mechanism diagram as though it were a results table.

5-Amino-1MQ Sits Alongside Other Metabolic Peptides Without Being Ranked Above or Below Them#

There is no single most powerful peptide for fat loss, and the phrase itself collapses several distinct questions into one. Effect size, evidence quality, safety record, route of administration and regulatory status vary independently across the metabolic category, and a compound can look strong on one axis and thin on another.

5-Amino-1MQ illustrates the point. Its mechanism is unusually well characterised at the enzyme level, and its rodent fat mass data is reproducible across independent studies. Its human evidence is absent. Other compounds in the metabolic category invert that profile, with human data but different mechanisms and different constraints. Those are different profiles, not a hierarchy.

Klarovel does not sort compounds into tiers or grades, and searching for the most powerful peptide for fat loss will not produce a defensible ranking from the published literature. Each compound gets its evidence stage stated instead, so a molecule carrying only rodent data is neither dressed up as more than it is nor dismissed for being early. The weighing is the reader's.

A Klarovel Protocol Frame Helps Track Dose, Duration, and Response Over Time#

A structured protocol frame turns an uncontrolled experiment into a documented one. For a compound with no human trial record, that documentation is the only signal a person will ever have about their own response, which makes recording it more valuable here than for well-studied compounds, not less.

The frame is simple: log the amount taken, the format, the timing, the start date, and a small number of outcome measures tracked on a fixed schedule. Body composition, waist measurement, training output and subjective energy all work, provided the measurement method does not change mid-cycle. Fixed review points, rather than continuous self-assessment, reduce the noise.

Blood work is optional in the Klarovel frame and is never a prerequisite for starting a protocol. Some people want baseline metabolic markers; others do not, and that is a personal choice rather than a gate.

You can build and track a cycle with the peptide calculator, see the method in how it works, or create an account to keep protocol records in one place.

The Interesting Part and the Missing Part Are Both Real#

5-Amino-1MQ deserves neither the hype nor the dismissal it usually receives. The enzyme target is well characterised, the rodent fat mass data is reproducible across independent groups, and the SAM-sparing mechanism is genuinely distinct from NAD+ precursor supplementation. The human trial column is also completely empty, and that stays true no matter how good the mechanism diagram looks. Both statements belong in the same sentence, every time.

Build your cycle on record rather than on recall: set up a tracked protocol with the peptide calculator, or create your Klarovel account and keep dose, duration and response in one place from day one.